Triple threat: new combo targets nasopharyngeal cancer spread
NCT ID NCT05524168
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining targeted radiation (SBRT) with an immunotherapy drug (camrelizumab) and standard chemotherapy can help control nasopharyngeal cancer that has spread to a few other parts of the body. The study involves 41 participants who have not had prior treatment for their metastatic disease. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Camrelizumab (PD-1 antibody), gemcitabine, cisplatin, and SBRT (radiation)
- What this could lead to
- If successful, this combination could offer a new treatment option to control cancer spread and delay progression in patients with nasopharyngeal carcinoma that has spread to a few spots.
- What could go wrong
- This is a small, early-phase trial with only 41 participants and no comparison group. The treatment may cause significant side effects from chemotherapy, immunotherapy, and radiation, and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers